LEAD 2

HOW MANY WEEKS IS THE LEAD 2 STUDY?

26 WEEKS
WHAT WAS THE STUDY DESIGN FOR THE LEAD 2 STUDY?

RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND AACTIVE CONTROL GROUP
HOW WAS THE AUTHOR OF LEAD 2

NAUCK
WHAT WERE THE INCLUSION CRITERIA FOR LEAD 2
- 7-11% FOR PATIENTS ON PREVIOUS OAD MONOTHERAPY >3 MONTHS
- 7-10% for patients for previous oad combinations therapy >3 months
- MEAN A1C 8.4%
AGE 18-80 YEARS
PRIMARY OUTCOME MEASURE FOR LEAD 2

CHANGE IN A1C AFTER 26 WEEKS
SECONDARY EFFICACY IN LEAD 2

CHANGE IN BODY WEIGHT, FPG , BETA CELL FUNTION SBP
WHAT WAS THE CHANGE IN BODY WEIGHT IN LEAD 2

0.6 -3.96

1.2 -5.72

1.8 -6.16

GLIM 4.0 +2.2
PERCENTAGE OF PATIENTS THAT REACHED ADA GOAL IN LEAD 2 IN MONOTHERAPY ARM

1.2MG 52.8

1.8MG 66.3
WHAT WERE THE MINOR HYPO RATES IN THE LEAD 2 STUDY?
0.6MG 3.3

1.2MG 0.8
- 1.8MG 2.5
- GLIM 16.9

Author

Susanslcm

45577

Card Set

LEAD 2

Description

EFFICACY AND SAFETY COMPARISON OF LIRAGLUTIDE, GLIMEPRIDE ADN PLACEBO. ALL IN COMBINATION WITH METFORMIN IN T2 DIABETES

Updated

2010-10-28T01:47:19Z